<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581812</url>
  </required_header>
  <id_info>
    <org_study_id>HR-17/18-5341</org_study_id>
    <nct_id>NCT03581812</nct_id>
  </id_info>
  <brief_title>Snack Foods and Their Impact on Gastrointestinal Microbiology, Function and Symptoms</brief_title>
  <acronym>OptiGut</acronym>
  <official_title>Snack Foods and Their Impact on Gastrointestinal Physiology, Luminal Microbiology and Gastrointestinal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of replacing usual snacks with&#xD;
      alternative snack foods on gut health in a population of habitual snackers with low fibre&#xD;
      intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diet is a crucial target for the improvement of human health. In the modern world, diets are&#xD;
      diverse and diet related diseases are becoming more and more common. In particular, it is&#xD;
      becoming increasingly apparent that the bacteria that live in the gut are strongly linked to&#xD;
      both diet and health. Bacteria in the gut can be beneficial or harmful, and the health of the&#xD;
      gut relies on the beneficial bacteria outnumbering the harmful ones. Diet has a great impact&#xD;
      on the bacterial composition of the gut. In turn, the gut bacteria play diverse roles in&#xD;
      human health, influencing not only the gut but also the health of the immune system, heart&#xD;
      and brain. Therefore, optimising the composition of the gut bacterial is vital to human&#xD;
      health and wellbeing.&#xD;
&#xD;
      It has been shown that snacks between meals contributes 420 - 480 calories per day, almost a&#xD;
      quarter of the recommended intake. Therefore, snack choices are an area of diet and lifestyle&#xD;
      that have the potential to influence diet and in turn the health of our gut and gut bacteria.&#xD;
      We would like to assess the effect of replacing usual snacks with alternative snack foods&#xD;
      that we believe have benefits for gut health.&#xD;
&#xD;
      The primary aim of the study is to investigate whether the replacement of usual snacks has an&#xD;
      effect on gut bacterial composition, specifically the abundance of Bifidobacteria. Secondary&#xD;
      aims include the effect of the intervention snacks on additional measures of gut health such&#xD;
      as gut transit time, the frequency and consistency of bowel movements and gut symptoms e.g.&#xD;
      heartburn, nausea, belching etc. The effect of snack foods on metabolites in the blood (e.g.&#xD;
      glucose, insulin, lipids) will also be determined. Finally the impact of snack replacement on&#xD;
      mood and quality of life will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Faecal bifidobacteria</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from participant stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Faecal bifidobacteria</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from participant stool samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole gut transit time</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole gut transit time</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional gut transit time</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional gut transit time</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional gut pH</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional gut pH</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured using the SmartPill wireless motility capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal gut microbiota (alpha- and beta-diversity)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from participant stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal gut microbiota (alpha- and beta-diversity)</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from participant stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal short-chain fatty acids (SCFA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by gas liquid chromatography of stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal short-chain fatty acids (SCFA)</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured by gas liquid chromatography of stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal water</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by lyophilization of stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal water</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured by lyophilization of stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal volatile organic compounds</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by gas-chromatography mass-spectrometry of stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal volatile organic compounds</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured by gas-chromatography mass-spectrometry of stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut symptoms</measure>
    <time_frame>Week 0</time_frame>
    <description>Gastrointestinal symptoms rating scale (7-day; questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut symptoms</measure>
    <time_frame>week 4</time_frame>
    <description>Gastrointestinal symptoms rating scale (7-day; questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Week 0</time_frame>
    <description>Bristol stool form scale (7-day; questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Week 4</time_frame>
    <description>Bristol stool form scale(7-day; questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Week 0</time_frame>
    <description>7-day food diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Week 4</time_frame>
    <description>7-day food diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Day 28</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Baseline</time_frame>
    <description>Hospital anxiety and depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Day 28</time_frame>
    <description>Hospital anxiety and depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Recent physical activity questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Day 28</time_frame>
    <description>Recent physical activity questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary metabolites (various)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary metabolites (various)</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Particle size of masticated snack foods</measure>
    <time_frame>Day 28</time_frame>
    <description>Mechanical sieving and laser diffraction of masticated snack foods</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>From baseline - day 28</time_frame>
    <description>Interview-administered questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of snack products</measure>
    <time_frame>Day 28</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Human Microbiome</condition>
  <condition>Eating Behavior</condition>
  <arm_group>
    <arm_group_label>Intervention snack 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention snack 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control snack</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control snack food reflecting the macro-nutrient profile of a typical UK snack.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intervention snack 1</intervention_name>
    <description>To be eaten instead of regular snacks twice a day for 4 weeks.</description>
    <arm_group_label>Intervention snack 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intervention snack 2</intervention_name>
    <description>To be eaten instead of regular snacks twice a day for 4 weeks.</description>
    <arm_group_label>Intervention snack 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control snack</intervention_name>
    <description>To be eaten instead of regular snacks twice a day for 4 weeks.</description>
    <arm_group_label>Control snack</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Aged between 18-45 years&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 - 29.9 kg/m2&#xD;
&#xD;
          -  Regular consumption of snacks (≥2 per day, excluding fruit and nut snacks)&#xD;
&#xD;
          -  Low fibre intake (&lt;22 g/d)&#xD;
&#xD;
          -  Willing to follow the protocol and provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or intolerance to snack ingredients (assessed at screening)&#xD;
&#xD;
          -  Dislike of study snacks&#xD;
&#xD;
          -  Regular consumption of intervention foods as snacks (twice a day in last month)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Major active psychiatric conditions (e.g. schizophrenia) or current eating disorder&#xD;
&#xD;
          -  Active treatment for cancer in the last year&#xD;
&#xD;
          -  Severe renal, cardiac or pulmonary disease or any other chronic medical condition&#xD;
&#xD;
          -  Severe oesophagitis, gastritis or duodenitis&#xD;
&#xD;
          -  Active diverticulitis or intestinal/colonic strictures&#xD;
&#xD;
          -  Crohns disease or Ulcerative colitis&#xD;
&#xD;
          -  Abdominal surgery (except appendicectomy or cholecystectomy)&#xD;
&#xD;
          -  Irritable bowel syndrome&#xD;
&#xD;
          -  Functional constipation&#xD;
&#xD;
          -  Functional diarrhoea&#xD;
&#xD;
          -  Antibiotics (past 4 weeks)&#xD;
&#xD;
          -  Ongoing therapy with drugs affecting gastrointestinal motility&#xD;
&#xD;
          -  Use of medical devices (Pacemakers, infusion pumps, insulin pumps)&#xD;
&#xD;
          -  Women who are pregnant/lactating/planning pregnancy&#xD;
&#xD;
          -  Recent/ongoing consumption of probiotics/prebiotics (past 4 weeks)&#xD;
&#xD;
          -  Ongoing abuse of alcohol/drugs/other medication&#xD;
&#xD;
          -  Very high physical activity levels&#xD;
&#xD;
          -  Unexplained/unintentional weight loss in the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Whelan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College London Waterloo Campus</name>
      <address>
        <city>London</city>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Professor Kevin Whelan</investigator_full_name>
    <investigator_title>Professor of Dietetics</investigator_title>
  </responsible_party>
  <keyword>Gut Microbiota</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Gut Health</keyword>
  <keyword>Snack</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

